arrow
S

Shadmehr Demehri

Harvard Medical School
H指数:34
被引数:4,782

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Summary recommendations from the National Cancer Institute Clinical Trials Planning Meeting on advanced cutaneous squamous cell carcinoma in immunosuppressed patients

国家癌症研究所临床 trials 规划会议关于免疫抑制患者中晚期皮肤鳞状细胞癌的摘要建议

2026-07-210
PRE
Association of Macrophage Migration Inhibitory Factor (MIF) with Therapy Response and Clinical Outcomes in HPV-Related Head and Neck Squamous Cell Carcinoma: A Preliminary Report

巨噬细胞迁移抑制因子(MIF)与HPV相关头颈鳞状细胞癌治疗反应及临床结局的关联:初步报告

2026-05-010
OA
CoREST complex inhibition alters RNA splicing to promote neoantigen expression and enhance tumor immunity

CoREST复合物抑制改变RNA剪接以促进新抗原表达并增强肿瘤免疫

2026-01-230
PRE
BATF2 is a glutamine-responsive tumour suppressor required for type-I interferon-dependent anti-tumour immunity

BATF2是一种对谷氨酰胺敏感的肿瘤抑制因子,是I型干扰素依赖性抗肿瘤免疫所必需的。

2025-12-290
OAAI
BATF2 is a glutamine-responsive tumor suppressor essential for type I interferon-dependent anti-tumor immunity
2025-11-010
PRE
Type 2 Immunity Links Eczematous and Lichenoid Eruptions Caused by Immune Checkpoint Inhibitors

2型免疫将免疫检查点抑制剂引起的湿疹样和苔藓样皮疹联系起来

2025-08-080
PRE
Hepatitis B virus promotes liver cancer by modulating the immune response to environmental carcinogens

黄,M.; 王,D.; 黄,J.; Bae, A.N.; 夏,Y.; 赵,X.; Mortaja, M.; Azin, M.; Collier, M.R.; Semenov, Y.R.; 等. 乙型肝炎病毒通过调节对环境致癌物的免疫反应促进肝癌。Nat. Commun. 2025, 16, 5360. [Google Scholar] [CrossRef] [PubMed]

2025-06-270
OAAI
Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events

接受度普利尤单抗治疗皮肤免疫相关不良事件的患者长期死亡率结局

2025-05-120
OA